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Differences of Inflammatory
Mechanisms in Asthma and COPD
Masakazu Ichinose1
ABSTRACT
Bronchial asthma and chronic obstructive pulmonary disease (COPD) are increasing common diseases. The
major pathogenesis of both illnesses is chronic inflammation. However, the inflammatory pattern is distinct in
each disease. In asthmatic airways, activated mast cellseosinophils and T helper 2 lymphocytes (Th2) are
predominant. In contrast, macrophages and neutrophils are important in COPD airwayslung. Although nitric
oxide (NO) hyperproduction due to inducible NO synthase (iNOS) is observed in asthma and COPD, nitrotyro-
sine formation via the reaction between NO and O2− in addition to the myeloperoxidase-mediated pathway.
These distinct inflammatory patterns in both diseases seem to cause pathological differences in asthma and
COPD.
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INTRODUCTION
Both bronchial asthma and chronic obstructive pul-
monary disease (COPD) are defined as inflammatory
diseases in recent worldwide guidelines,1,2 although
the inflammatory process for each disease is differ-
ent. In this review, I describe some differences in the
inflammatory processes in each disease.
INFLAMMATORY CELL INFILTRATION
Bronchial asthma is characterized as chronic airway
inflammation from the central to the peripheral air-
ways involving various cell types such as activated
mast cellseosinophils and T helper 2 lymphocytes
(Th2), which release mediators that contribute to
asthma symptoms (Table 1).1,3-10 Actually, many cy-
tokines and growth factors such as IL-4, IL-5, and
GM-CSF can be monitored with exhaled breath con-
densate (EBC) (Table 2).11 Clinically, examination of
the eosinophil infiltration into the airways (sputum) is
useful for discriminating asthma from COPD.12,13
On the other hand, in COPD, the inflammatory
cells that infiltrate into the airwayslung are different
(Fig. 1).13 Macrophages are increased in the lungs of
patients with asthma and COPD, however, they are
more increased in COPD than in asthma. These
macrophages are derived from circulating mono-
cytes, which migrate to the lungs in response to
chemoattractants such as CC-chemokine ligand 2
(CCL2), also known as MCP1, acting on CCR2, and
CXCL1 acting on CXCR2.14
Neutrophils are also increased in the sputum of pa-
tients with COPD and are correlated with the disease
severity.15
However, during exacerbations in both diseases,
inflammatory cell infiltration into the airways be-
comes less selective, that is, there is neutrophil infil-
tration in asthma and eosinophil accumulation in
COPD, possibly due to virus-induced chemokine pro-
duction via the epithelium.
MEDIATORS THAT ACT ON THE BRON-
CHOMOTOR TONE
In asthma, cysteinyl leukotrienes are potent bron-
choconstrictors and proinflammatory mediators
mainly derived from mast cells and eosinophils. They
are the only mediator whose inhibition has been asso-
ciated with an improvement in lung function and
asthma symptoms.1,16 Histamine and prostaglandins
are also released from mainly mast cells and contrib-
ute to the bronchomotor tone in asthma.1 Therefore,
functional antagonists, such as β2-stimulants, cause
more potent bronchodilation than anti-cholinergic
agents in bronchial asthma.
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Mast cels: Activated mucosal mast cels release bronchoconstrictor mediators (histamine, cysteinyl leukotrienes, prostaglan-
din D2) (3). These cels are activated by alergens through high-afinity IgE receptors, as wel as by osmotic stimuli (accounting 
for exercise-induced bronchoconstriction). Increased mast cel numbers in airway smooth muscle may be linked to airway hyper-
responsiveness (4).
Eosinophils, present in increased numbers in the airways, release basic proteins that may damage airway epithelial cels. They 
may also have a role in the release of growth factors and airway remodeling (5).
T lymphocytes, present in increased numbers in the airways, release specific cytokines, including IL-4, IL-5, IL-9, and IL-13, 
that orchestrate eosinophilic inflammation and IgE production by B lymphocytes (6). An increase in Th2 cel activity may be due 
in part to a reduction in regulatory T cels that normaly inhibit Th2 cels. There may also be an increase in invariant T cels, 
which release large amounts of T helper 1 (Th1) and Th2 cytokines (7).
Dendritic cels sample alergens from the airway surface and migrate to regional lymph nodes, where they interact with regula-
tory T cels and ultimately stimulate the production of Th2 cels from naïve T cels (8).
Macrophages are increased in the airways and may be activated by alergens through low-afinity IgE receptors to release in-
flammatory mediators and cytokines that amplify the inflammatory response (9).
Neutrophils are increased in the airways and sputum of patients with severe asthma and in smoking asthmatics, but the patho-
physiological role of these cels is uncertain and their increase may even be due to glucocorticosteroid therapy (10).
Reproduced from reference 1.
Table 1 Inflammatory cels in asthmatic airways 
Fold 
increase(b/a)
Asthmatic
subjects (%)(b)
Control subjects
(%)(a)Cytokine
Fold 
increase(b/a)
Asthmatic
subjects (%)(b)
Control subjects
(%)(a)Cytokine
1.528.3 ± 1.9*5.4 ± 2.1IL-81.305.2 ± 1.34.0 ± 2.1IL-1α
0.974.1 ± 1.54.2 ± 1.4Mig0.924.2 ± 2.04.6 ± 0.9IL-1β
2.7222.7 ± 6.4*8.4 ± 1.3IP-100.834.1 ± 2.04.9 ± 1.7IL-2
1.003.5 ± 2.23.5 ± 1.5I-3090.885.0 ± 2.05.7 ± 1.4IL-3
1.479.2 ± 2.0*6.3 ± 1.3MIP-1α1.568.2 ± 1.6*5.2 ± 1.7IL-4
1.5810.2 ± 3.7*6.5 ± 1.5MIP-1β0.914.7 ± 1.75.2 ± 1.2IL-6
1.455.4 ± 2.93.7 ± 1.3MIP-1δ0.914.6 ± 1.85.1 ± 1.3IL-6sR
1.6910.4 ± 2.5*6.2 ± 1.5RANTES1.243.2 ± 1.52.6 ± 0.8IL-7
1.207.9 ± 2.26.5 ± 2.1MCP-11.045.7 ± 1.65.4 ± 1.8IL-10
1.044.3 ± 1.54.1 ± 1.7MCP-20.935.2 ± 1.85.6 ± 1.8IL-11
1.095.0 ± 2.34.6 ± 2.2Eotaxin-10.884.2 ± 1.84.8 ± 1.4IL-12 p40
1.114.3 ± 1.33.9 ± 1.7Eotaxin-21.243.4 ± 2.12.8 ± 1.4IL-12 p70
0.883.1 ± 1.53.6 ± 1.7G-CSF1.375.5 ± 2.34.0 ± 1.0IL-13
0.923.4 ± 1.63.8 ± 1.0GM-CSF1.017.4 ± 3.47.3 ± 2.8IL-15
0.979.4 ± 4.79.7 ± 3.4M-CSF1.046.5 ± 4.36.2 ± 1.8IL-16
1.6911.6 ± 3.4*6.6 ± 1.2TGF-β1.4612.6 ± 4.1*8.6 ± 1.5IL-17
1.127.6 ± 1.86.8 ± 1.6PDGF1.7612.4 ± 3.8*7.0 ± 1.0TNF-α
0.949.0 ± 3.09.5 ± 2.9TIMP-21.0027.6 ± 8.327.7 ± 7.4 TNF-β
1.003.4 ± 2.13.4 ± 0.8ICAM-11.135.4 ± 1.44.8 ± 1.8sTNF RI
1.005.5 ± 2.25.4 ± 2.2IFN-γ0.904.6 ± 1.55.1 ± 1.6sTNF RI
Abbreviations: Mig, monokine induced by IFN-g; IL-6sR, IL-6 soluble receptor; MCP, monocyte chemoatractant protein; G-
CSF, granulocyte colony-stimulating factor; M-CSF, macrophage colony-stimulating factor; PDGF, platelet-derived growth fac-
tor; TIMP-2, tissue inhibitor of metaloprotease 2; sTNF-R, soluble TNF receptor; ICAM-1, intracelular adhesion molecule 1. 
*P < .01 compared with control subjects. Reproduced from reference 5.
Table 2 Relative cytokine levels to positive control in exhaled breath condensates (EBC) obtained from either healthy sub-
jects (a) or asthmatic subjects (b)
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Fig. 1 Inflammatory cels involved in COPD. Inhaled cigarete smoke activates epithelial cels 
and macrophages to release several chemotactic factors that atract inflammatory cels to the 
lungs, such as CC-chemokine ligand 2 (CCL2), which acts on CC-chemokine receptor 2 (CCR2) 
to atract monocytes, CXC-chemokine ligand 1 (CXCL1) and CXCL8, which act on CCR2 to at-
tract neutrophils and monocytes (which diferentiate into macrophages in the lungs) and CXCL9, 
CXCL10 and CXCL11, which act on CXCR3 to atract T helper 1 (TH1) cels and type 1 cytotoxic 
T (TC1) cels. These inflammatory cels together with macrophages and epithelial cels release 
proteases, such as matrix metaloproteinase 9 (MMP9), which cause elastin degradation and 
emphysema. Neutrophil elastase also causes mucus hypersecretion. Epithelial cels and macro-
phages also release transforming growth factor-β (TGFβ), which stimulates fibroblast proliferation, 
resulting in fibrosis in the smal airways. Reproduced from reference 13.
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In contrast, in COPD patients, such inflammatory
mediators are not important for the bronchomotor
tone. In COPD airways, anti-cholinergic agents shows
more obvious bronchodilatory effects than β2-
stimulants, indicating that vagal nerve-derived acetyl-
choline is the only bronchoconstrictive (reversible)
mechanism in this disease.17
TACHYKININS
Because tachykinins, such as substance P (SP) and
neurokinin A (NKA), are potent stimulants of submu-
cosal glands and goblet cell secretion,16 these pep-
tides seem to be involved in the inflammatory process
in asthma and COPD. Increased SP concentrations
have been reported in the induced sputum of patients
with asthma and COPD compared with healthy indi-
viduals (Fig. 2).18 SP is metabolized by neutral end-
peptidase (NEP),19 which exists in the respiratory
epithelium. In asthmatic airways, epithelium shed-
ding caused by eosinophil-derived major basic pro-
tein (MBP)20,21 leads to dysfunction of the NEP,
which may enhance the tachykinins’ function. Actu-
ally, there was a significant relation between the
eosinophil count and SP concentration in the induced
sputum from patients with asthma but not in that
from COPD subjects.18 These data suggest that SP
Ichinose M
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Fig. 2 Left panel: Substance P (SP) concentration in hypertonic saline-induced sputum. Bars indicate mean values. 
Right panel: Relation between SP concentration and FEV1/FVC. r is corelation coeficient; the line and p value cor-
respond to the fited regression equation. Reproduced from reference 18 with modification.
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hypo-degradation due to epithelial loss may be the
cause of the elevated SP levels in asthmatic airways.
Tachykinin antagonists have been administrated to
asthmatic subjects, and have shown clinical benefits
in bradykinin- and exercise-induced asthma (Fig. 3,
4).22,23 There are no reported studies of tachykinin
antagonists in COPD subjects.16
NITRIC OXIDE (NO) AND OTHER OXIDA-
TIVE MOLECULES
Because reactive oxygen and related species includ-
ing nitric oxide (NO) have a potent proinflammatory
action,24,25 these molecules may be involved in the
airway inflammatory process in asthma.26 In animal
models, allergen-27 and ozone-induced28 airway in-
flammation and airway hyperresponsiveness are
largely modified by inhibitors of synthesis of reactive
oxygen and related species or by scavengers of radi-
cal species, supporting this hypothesis. Further, NO
hyperproduction due to inducible NO synthase
(iNOS) has been shown in asthmatic airways and ex-
perimental asthma animal models.29-33 Steroid treat-
ment reduces the NO generation,34 suggesting that
NO may be partly responsible for the asthmatic air-
way inflammation.
Other types of reactive oxygen, such as superoxide
anion (O2−) may also be exaggerated in asthmatic air-
ways via the upregulation of xanthine oxidase (XO) in
microvascular endothelial cells and NADPH oxidase
in the infiltrated eosinophils.35 NO rapidly reacts with
O2− released from inflammatory cells including
eosinophils, and results in the formation of the highly
proinflammatory molecule peroxynitrite.36
NO seems to be involved in the inflammatory
mechanism of the late allergic response (LAR) after
allergen challenge, which most resembles asthmatic
airway inflammation. We have assessed the NO, O2−
and peroxynitrite production by measuring the NO
concentration in the exhaled air, O2− generating en-
zyme activity, and peroxynitrite-induced nitration
product immunostaining, respectively. We quantified
the airway microvascular permeability by means of
Monastral blue dye trapping between the postcapil-
lary endothelium. The functional role of the NO, O2−
and peroxynitrite on the microvascular permeability
was assessed using each molecule’s synthase inhibi-
tor or scavenger. Further, we also quantified the
eosinophil accumulation into the airways during the
LAR and examined the role of NO, O2− and peroxyni-
trite in the eosinophil response. We have reported
that peroxynitrite formed by NO and O2− is an impor-
tant molecule for the microvascular hyperpermeabil-
ity but not the eosinophil accumulation during the
late allergic airway responses.37
Oxidative stress and defense imbalance may be
one of the causes of COPD.38-41 The large production
of NO during inflammatory-immune processes of the
respiratory tract is thought to constitute a host de-
fense mechanism, although this comes at a price be-
cause a high level of NO can also cause respiratory
tract injury and thus contribute to the pathophysiol-
ogy of inflammatory airway diseases such as COPD
and asthma. Recently, excessive nitric oxide (NO)
production, presumably via inducible NO synthase
(iNOS), has been reported in asthmatic airways,41 al-
though its presence is controversial in COPD air-
ways.
The adverse effects of NO are thought to be engen-
dered, in part, by its reaction with superoxide anion,
which is released from inflammatory cells, yielding
the potent oxidant peroxynitrite.36 Peroxynitrite adds
a nitro group to the 3-position adjacent to the hy-
Inflammatory Mechanisms in Asthma and COPD
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Fig. 3 Dose-response relation to bradykinin in each subject. ○ indicates 
after placebo and ● indicates after FK 224 (NK 1, 2-antagonist). Repro-
duced from reference 22.
sG
aw
 (
%
 o
f b
as
el
in
e)
100
80
60
40
20
100
80
60
40
20
1 2
0 4.9 20 78 310 1250
100
80
60
40
20
3
0 4.9 20 78 310 1250
100
80
60
40
20
6
0 20 78 310 1250
100
80
60
40
20
8
0 4..9 20 78 310 1250
0 4..9 20 78 310 1250
100
80
60
40
20
4
0 4..9 20 78 310 1250
100
80
60
40
20
7
0 4..9 20 78 310 1250
100
80
60
40
20
9
0 4.9 20 78 310 1250
100
80
60
40
20
10
0 4.9 20 78 310 1250
Cumulative bradykinin concentration (µg/ml)
FK-224
Placebo
4.9
droxyl group of tyrosine to produce the stable prod-
uct nitrotyrosine. Alternatively, NO reacts with O2 to
form nitrite. The oxidation of nitrite by neutrophil-
derived myeloperoxidase (MPO) or by other related
peroxidases42 results in the formation of nitryl chlo-
ride and nitrogen dioxide (NO2). This mechanism
has also been found in inflammatory conditions. Al-
though tyrosine nitration is generally attributed to
peroxynitrite, the peroxidase-dependent nitrite oxida-
tion pathway is also involved. Therefore, nitrotyrosine
is a collective indicator for the involvement of reactive
nitrogen species. We have reported that abundant ni-
trotyrosine positive staining cells as well as iNOS
positive cells were observed in the induced sputum
both in COPD and asthmatic patients compared with
healthy subjects.43 The nitrotyrosine positive cells
were significantly more obvious in COPD than in
asthma, suggesting that the oxidative stress by reac-
Ichinose M
312 Allergology International Vol 58, No3, 2009 www.jsaweb.jp
Fig. 4 Relation between %predicted FEV1 and nitrotyrosine (NT)-positive cel counts in 
induced sputum of asthma and COPD patients. r is corelation coeficient; the line and p 
value corespond to the fited regression equation. N.S. , not significant. Reproduced from 
reference 43.
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p < 0.05
tive nitrogen species may be exaggerated in the air-
ways of these diseases, especially in COPD. Further,
because the nitrotyrosine positive cell counts were
significantly correlated with the airway obstructive
changes in COPD (Fig. 4),43 the hyperproduction of
reactive nitrogen species may be an important factor
in the pathogenesis of COPD. Further, in COPD pa-
tients, the steroid-induced improvement in the airway
caliber and hyperresponsiveness is significantly cor-
related with the reduction of the reactive nitrogen
species production,44 indicating that modulation of
the reactive nitrogen species may be useful for future
COPD therapy.
CONCLUSION
In this review, I have shown some aspects of the dif-
ferences of the inflammatory processes in asthma
and COPD. These differences seem to cause distinct
pathological differences between the two diseases.45
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